Effective March 21st, 2023, DrFirst will no longer enforce entry of the X-Waiver number (NADEAN) when prescribing buprenorphine products within its e-prescribing applications.
With the signing of the Consolidated Appropriations Act of 2023, Congress eliminated the Data-Waiver Program removing the federal requirement for an X-Waiver number (NADEAN) when prescribing buprenorphine for opioid use disorder (OUD).
Going forward, prescribers with Schedule III and above prescribing authority can prescribe buprenorphine products for OUD if permitted by state law.
In accordance with this Act and DEA guidance, effective March 21st, 2023, DrFirst will no longer enforce entry of the Data Waiver (X-Waiver) when prescribing buprenorphine products within its e-prescribing applications.